Alan List. Tianjin Medical University Cancer Institute and Hospital
December 19, 2019 10:42 AM ESTUpdated 11:57 AM
China
Discovery

NIH-di­rect­ed purge of re­searchers with Chi­na ties sweeps up Mof­fitt CEO Alan List, col­leagues

Amber Tong

In an es­ca­la­tion of the al­ready height­ened sen­ti­ments around threats of aca­d­e­m­ic es­pi­onage, Mof­fitt Can­cer Cen­ter said Alan List, its pres­i­dent and CEO, and cen­ter di­rec­tor Thomas Sell­ers have re­signed for vi­o­lat­ing con­flict of in­ter­est rules through their work in Chi­na.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

A service from the Financial Times